Literature DB >> 17845147

Targeting tumour-associated macrophages.

Antonio Sica1, Luca Rubino, Alessandra Mancino, Paola Larghi, Chiara Porta, Monica Rimoldi, Graziella Solinas, Massimo Locati, Paola Allavena, Alberto Mantovani.   

Abstract

Clinical and experimental evidence have highlighted that a major leukocyte population present in tumours, the so-called tumour-associated macrophages (TAM), is the principal component of the leukocyte infiltrate supporting tumour growth. Over the years the mechanisms supporting the protumoural functions of TAM have become increasingly clear and in several experimental tumour models, the activation of an inflammatory response (most frequently mediated by macrophages) has been shown to play an essential role for full neoplastic transformation and progression. This evidence strongly supports the idea that TAM are central orchestrators of the inflammatory networks expressed in the tumour microenvironment, and suggest these cells as possible targets of anticancer therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17845147     DOI: 10.1517/14728222.11.9.1219

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  19 in total

Review 1.  Biobehavioral factors and cancer progression: physiological pathways and mechanisms.

Authors:  Susan K Lutgendorf; Anil K Sood
Journal:  Psychosom Med       Date:  2011-10-21       Impact factor: 4.312

2.  Neutrophils express oncomodulin and promote optic nerve regeneration.

Authors:  Takuji Kurimoto; Yuqin Yin; Ghaith Habboub; Hui-Ya Gilbert; Yiqing Li; Shintaro Nakao; Ali Hafezi-Moghadam; Larry I Benowitz
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

Review 3.  Macrophages are important mediators of either tumor- or inflammation-induced lymphangiogenesis.

Authors:  Rui-Cheng Ji
Journal:  Cell Mol Life Sci       Date:  2011-10-08       Impact factor: 9.261

4.  IL-10 contributes to the suppressive function of tumour-associated myeloid cells and enhances myeloid cell accumulation in tumours.

Authors:  L-X Wang; F Talebian; J-Q Liu; M Khattabi; L Yu; X-F Bai
Journal:  Scand J Immunol       Date:  2012-03       Impact factor: 3.487

5.  Sesamin inhibits macrophage-induced vascular endothelial growth factor and matrix metalloproteinase-9 expression and proangiogenic activity in breast cancer cells.

Authors:  Chun-Chung Lee; Ko-Jiunn Liu; Yu-Chen Wu; Sue-Jane Lin; Ching-Chun Chang; Tze-Sing Huang
Journal:  Inflammation       Date:  2011-06       Impact factor: 4.092

6.  Doxorubicin Hydrochloride Loaded Zymosan-Polyethylenimine Biopolymeric Nanoparticles for Dual 'Chemoimmunotherapeutic' Intervention in Breast Cancer.

Authors:  Vivek K Pawar; Yuvraj Singh; Komal Sharma; Arpita Shrivastav; Abhisheak Sharma; Akhilesh Singh; Jaya Gopal Meher; Pankaj Singh; Kavit Raval; Himangshu K Bora; Dipak Datta; Jawahar Lal; Manish K Chourasia
Journal:  Pharm Res       Date:  2017-06-12       Impact factor: 4.200

Review 7.  Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

Review 8.  Macrophages define the invasive microenvironment in breast cancer.

Authors:  Jeffrey W Pollard
Journal:  J Leukoc Biol       Date:  2008-05-08       Impact factor: 4.962

9.  Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.

Authors:  Jaehyup Kim; Ryan A Denu; Bridget A Dollar; Leah E Escalante; Justin P Kuether; Natalie S Callander; Fotis Asimakopoulos; Peiman Hematti
Journal:  Br J Haematol       Date:  2012-05-15       Impact factor: 6.998

10.  Adenoviral-mediated endothelial precursor cell delivery of soluble CD115 suppresses human prostate cancer xenograft growth in mice.

Authors:  Trevor Lucas; Dietmar Abraham; Gerold Untergasser; Karin Zins; Erhard Hofer; Eberhard Gunsilius; Seyedhossein Aharinejad
Journal:  Stem Cells       Date:  2009-09       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.